SCHEMBL6208569

SCHEMBL6208569

CC(C)(C)[Si](C)(C)OCCC1C2CN(c3c(F)cc(NC(=O)OCc4ccccc4)cc3F)CC12

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 1/20 0.39
NPC1 O15118 1/20 0.39
ALDH1A1 P00352 1/20 0.39
TP53 P04637 1/20 0.39
MAPT P10636 1/20 0.39
TSHR P16473 1/20 0.39
RAB9A P51151 1/20 0.39
ATM Q13315 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
RORC P51449 4/20 0.39
POLB P06746 1/20 0.39
MGLL Q99685 3/20 0.38
SCD O00767 1/20 0.38
KDM1A O60341 2/20 0.37
MAOA P21397 2/20 0.37
MAOB P27338 2/20 0.37
ENPP2 Q13822 1/20 0.36
ROCK2 O75116 1/20 0.36
RCOR1 Q9UKL0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6478919 1.00 PTGDR2 (0.39) PTGDR2NPC1ALDH1A1TP53MAPT
SCHEMBL6478377 0.86 PTGDR2 (0.43) PTGDR2NPC1ALDH1A1TP53MAPT
SCHEMBL5291750 0.84 PTGDR2 (0.44) PTGDR2NPC1ALDH1A1TP53MAPT
SCHEMBL6478512 0.79 RORC (0.45) PTGDR2NPC1ALDH1A1TP53MAPT
SCHEMBL5300358 0.79 MGLL (0.52) PTGDR2NPC1ALDH1A1TP53MAPT
SCHEMBL6477799 0.79 MGLL (0.47) PTGDR2NPC1ALDH1A1TP53MAPT
SCHEMBL6477870 0.79 RORC (0.50) PTGDR2NPC1ALDH1A1TP53MAPT
SCHEMBL6210658 0.78 NPC1 (0.48) PTGDR2NPC1ALDH1A1TP53MAPT
SCHEMBL6477500 0.77 PTGDR2 (0.44) PTGDR2NPC1ALDH1A1TP53MAPT
SCHEMBL6477573 0.77 MGLL (0.43) PTGDR2NPC1ALDH1A1TP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1549641-A1 ANTIMICROBIAL 3.1.0 BICYCLIC OXAZOLIDINONE DERIVATIVES Pharmacia & Upjohn Company LLC (US) 2005-07-06 EP disclosed
US-6875784-B2 Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives PHARMACIA & UPJOHN COMPANY (US) 2005-04-05 US disclosed
US-20040127530-A1 Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives PHARMACIA & UPJOHN COMPANY 2004-07-01 US disclosed
WO-2004033451-A1 ANTIMICROBIAL [3.1.0] BICYCLIC OXAZOLIDINONE DERIVATIVES PHARMACIA & UPJOHN COMPANY LLC (US) 2004-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127530-A1 Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives OXA1L, CYP1B1, MT-CO1 PTGDR2 3810/4885NPC1 2062/4885ALDH1A1 345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.